AustralieFrV1, Main, Exploration, bibRecord, 008154

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C

Identifieur interne : 008154 ( Main/Exploration ); précédent : 008153; suivant : 008155

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C

Auteurs : Avidan U. Neumann [Israël] ; Stephen Pianko [Australie] ; Stefan Zeuzem [Allemagne] ; Eric M. Yoshida [Canada] ; Yves Benhamou [France] ; Moshe Mishan [Israël] ; John G. Mchutchison [États-Unis] ; Erik Pulkstenis [États-Unis] ; G. Mani Subramanian [États-Unis]

Source :

Journal of hepatology [ 0168-8278 ] ; 2009.

RBID : Pascal:09-0322362

Descripteurs français

Pascal (Inist)
- Hépatite virale C, Albinterféron alfa-2b, Peginterféron alfa-2a, Facteur prédictif, Traitement, Homme, Virus hépatite C, Génotype, Typage, Gastroentérologie, Antiviral, Immunomodulateur, Anticancéreux.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Albinterferon alfa-2b, Antineoplastic agent, Antiviral, Gastroenterology, Genotype, Hepatitis C virus, Human, Immunomodulator, Peginterferon alfa-2a, Predictive factor, Treatment, Typing, Viral hepatitis C.

Abstract

Background/Aims: Albinterferon alfa-2b is a novel, long-acting, fusion polypeptide that is dosed q2wk or q4wk. The predictive value of early virologic response during albinterferon alfa-2b or peginterferon alfa-2a treatment was investigated in interferon-naïve patients with genotype 1, chronic hepatitis C. Methods: Four hundred and fifty-eight patients were randomized to: albinterferon 900 or 1200 μg q2wk, or 1200 μg q4wk, or peginterferon 180 μg qwk. HCV RNA was measured by real-time PCR. A linear exhaustive search algorithm was used to determine the best SVR prediction algorithm in the per-protocol population (n = 368), with inclusion of key ITT analyses to assess impact. Results: SVR rate: 54-67% (P = NS between arms). Rapid initial virologic response rate at week 2 (RIVR; viral decline >2log₁₀IU/mL) was 32-50% and gave rise to positive predictive value of 88-97% for SVR. No initial virologic response at week 4 (NIVR; viral decline <2log₁₀IU/mL; viral load >5.5log₁₀IU/mL) demonstrated a 100% negative predictive value for SVR. A sequential prediction algorithm based on viral kinetics at weeks 2 and 4 identified four prediction groups that reliably predicted SVR, positively or negatively, in 65-72% of patients. Conclusions:Improved SVR prediction was obtained by integrating absolute levels and reduction of HCV RNA at treatment week 2 and 4. Patients with RIVR had a high likelihood of achieving SVR.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 002C89
to stream PascalFrancis, to step Curation: 003331
to stream PascalFrancis, to step Checkpoint: 002924
to stream Main, to step Merge: 008893
to stream Main, to step Curation: 008154

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C</title>
<author><name sortKey="Neumann, Avidan U" sort="Neumann, Avidan U" uniqKey="Neumann A" first="Avidan U." last="Neumann">Avidan U. Neumann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Bar-Ilan University, Goodman Faculty of Life Sciences, Bldg. 212, Rm. 210</s1>
<s2>52900 Ramat-Gan</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>52900 Ramat-Gan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pianko, Stephen" sort="Pianko, Stephen" uniqKey="Pianko S" first="Stephen" last="Pianko">Stephen Pianko</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Monash University Medical School</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Monash University Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>J. W. Goethe-University Hospital</s1>
<s2>Frankfurt</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yoshida, Eric M" sort="Yoshida, Eric M" uniqKey="Yoshida E" first="Eric M." last="Yoshida">Eric M. Yoshida</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Benhamou, Yves" sort="Benhamou, Yves" uniqKey="Benhamou Y" first="Yves" last="Benhamou">Yves Benhamou</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hôpital Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mishan, Moshe" sort="Mishan, Moshe" uniqKey="Mishan M" first="Moshe" last="Mishan">Moshe Mishan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Bar-Ilan University, Goodman Faculty of Life Sciences, Bldg. 212, Rm. 210</s1>
<s2>52900 Ramat-Gan</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>52900 Ramat-Gan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mchutchison, John G" sort="Mchutchison, John G" uniqKey="Mchutchison J" first="John G." last="Mchutchison">John G. Mchutchison</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Gastroenterology, Duke Clinical Research Institute</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Durham, NC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pulkstenis, Erik" sort="Pulkstenis, Erik" uniqKey="Pulkstenis E" first="Erik" last="Pulkstenis">Erik Pulkstenis</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Human Genome Sciences, Inc.</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rockville, MD</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G. Mani" last="Subramanian">G. Mani Subramanian</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Human Genome Sciences, Inc.</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rockville, MD</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0322362</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0322362 INIST</idno>
<idno type="RBID">Pascal:09-0322362</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C89</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003331</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002924</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002924</idno>
<idno type="wicri:doubleKey">0168-8278:2009:Neumann A:positive:and:negative</idno>
<idno type="wicri:Area/Main/Merge">008893</idno>
<idno type="wicri:Area/Main/Curation">008154</idno>
<idno type="wicri:Area/Main/Exploration">008154</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C</title>
<author><name sortKey="Neumann, Avidan U" sort="Neumann, Avidan U" uniqKey="Neumann A" first="Avidan U." last="Neumann">Avidan U. Neumann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Bar-Ilan University, Goodman Faculty of Life Sciences, Bldg. 212, Rm. 210</s1>
<s2>52900 Ramat-Gan</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>52900 Ramat-Gan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pianko, Stephen" sort="Pianko, Stephen" uniqKey="Pianko S" first="Stephen" last="Pianko">Stephen Pianko</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Monash University Medical School</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Monash University Medical School</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>J. W. Goethe-University Hospital</s1>
<s2>Frankfurt</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yoshida, Eric M" sort="Yoshida, Eric M" uniqKey="Yoshida E" first="Eric M." last="Yoshida">Eric M. Yoshida</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>University of British Columbia</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Benhamou, Yves" sort="Benhamou, Yves" uniqKey="Benhamou Y" first="Yves" last="Benhamou">Yves Benhamou</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hôpital Pitié-Salpêtrière</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mishan, Moshe" sort="Mishan, Moshe" uniqKey="Mishan M" first="Moshe" last="Mishan">Moshe Mishan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Bar-Ilan University, Goodman Faculty of Life Sciences, Bldg. 212, Rm. 210</s1>
<s2>52900 Ramat-Gan</s2>
<s3>ISR</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Israël</country>
<wicri:noRegion>52900 Ramat-Gan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mchutchison, John G" sort="Mchutchison, John G" uniqKey="Mchutchison J" first="John G." last="Mchutchison">John G. Mchutchison</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Gastroenterology, Duke Clinical Research Institute</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Durham, NC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pulkstenis, Erik" sort="Pulkstenis, Erik" uniqKey="Pulkstenis E" first="Erik" last="Pulkstenis">Erik Pulkstenis</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Human Genome Sciences, Inc.</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rockville, MD</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G. Mani" last="Subramanian">G. Mani Subramanian</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Human Genome Sciences, Inc.</s1>
<s2>Rockville, MD</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rockville, MD</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of hepatology</title>
<title level="j" type="abbreviated">J. hepatol.</title>
<idno type="ISSN">0168-8278</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of hepatology</title>
<title level="j" type="abbreviated">J. hepatol.</title>
<idno type="ISSN">0168-8278</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albinterferon alfa-2b</term>
<term>Antineoplastic agent</term>
<term>Antiviral</term>
<term>Gastroenterology</term>
<term>Genotype</term>
<term>Hepatitis C virus</term>
<term>Human</term>
<term>Immunomodulator</term>
<term>Peginterferon alfa-2a</term>
<term>Predictive factor</term>
<term>Treatment</term>
<term>Typing</term>
<term>Viral hepatitis C</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Hépatite virale C</term>
<term>Albinterféron alfa-2b</term>
<term>Peginterféron alfa-2a</term>
<term>Facteur prédictif</term>
<term>Traitement</term>
<term>Homme</term>
<term>Virus hépatite C</term>
<term>Génotype</term>
<term>Typage</term>
<term>Gastroentérologie</term>
<term>Antiviral</term>
<term>Immunomodulateur</term>
<term>Anticancéreux</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background/Aims: Albinterferon alfa-2b is a novel, long-acting, fusion polypeptide that is dosed q2wk or q4wk. The predictive value of early virologic response during albinterferon alfa-2b or peginterferon alfa-2a treatment was investigated in interferon-naïve patients with genotype 1, chronic hepatitis C. Methods: Four hundred and fifty-eight patients were randomized to: albinterferon 900 or 1200 μg q2wk, or 1200 μg q4wk, or peginterferon 180 μg qwk. HCV RNA was measured by real-time PCR. A linear exhaustive search algorithm was used to determine the best SVR prediction algorithm in the per-protocol population (n = 368), with inclusion of key ITT analyses to assess impact. Results: SVR rate: 54-67% (P = NS between arms). Rapid initial virologic response rate at week 2 (RIVR; viral decline >2log<sub>10</sub>
IU/mL) was 32-50% and gave rise to positive predictive value of 88-97% for SVR. No initial virologic response at week 4 (NIVR; viral decline <2log<sub>10</sub>
IU/mL; viral load >5.5log<sub>10</sub>
IU/mL) demonstrated a 100% negative predictive value for SVR. A sequential prediction algorithm based on viral kinetics at weeks 2 and 4 identified four prediction groups that reliably predicted SVR, positively or negatively, in 65-72% of patients. Conclusions:Improved SVR prediction was obtained by integrating absolute levels and reduction of HCV RNA at treatment week 2 and 4. Patients with RIVR had a high likelihood of achieving SVR.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Israël</li>
<li>États-Unis</li>
</country>
<region><li>District de Darmstadt</li>
<li>Hesse (Land)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Francfort-sur-le-Main</li>
<li>Paris</li>
</settlement>
</list>
<tree><country name="Israël"><noRegion><name sortKey="Neumann, Avidan U" sort="Neumann, Avidan U" uniqKey="Neumann A" first="Avidan U." last="Neumann">Avidan U. Neumann</name>
</noRegion>
<name sortKey="Mishan, Moshe" sort="Mishan, Moshe" uniqKey="Mishan M" first="Moshe" last="Mishan">Moshe Mishan</name>
</country>
<country name="Australie"><noRegion><name sortKey="Pianko, Stephen" sort="Pianko, Stephen" uniqKey="Pianko S" first="Stephen" last="Pianko">Stephen Pianko</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Zeuzem, Stefan" sort="Zeuzem, Stefan" uniqKey="Zeuzem S" first="Stefan" last="Zeuzem">Stefan Zeuzem</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Yoshida, Eric M" sort="Yoshida, Eric M" uniqKey="Yoshida E" first="Eric M." last="Yoshida">Eric M. Yoshida</name>
</noRegion>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Benhamou, Yves" sort="Benhamou, Yves" uniqKey="Benhamou Y" first="Yves" last="Benhamou">Yves Benhamou</name>
</region>
</country>
<country name="États-Unis"><noRegion><name sortKey="Mchutchison, John G" sort="Mchutchison, John G" uniqKey="Mchutchison J" first="John G." last="Mchutchison">John G. Mchutchison</name>
</noRegion>
<name sortKey="Pulkstenis, Erik" sort="Pulkstenis, Erik" uniqKey="Pulkstenis E" first="Erik" last="Pulkstenis">Erik Pulkstenis</name>
<name sortKey="Subramanian, G Mani" sort="Subramanian, G Mani" uniqKey="Subramanian G" first="G. Mani" last="Subramanian">G. Mani Subramanian</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008154 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008154 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:09-0322362
   |texte=   Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri